Alpha Tau Medical Ltd.
DRTS, DRTSW · Surgical & Medical Instruments & Apparatus · EDGAR filings ↗
Reference price $11.00 — last insider sale, 2026-06-25 (estimated from the dated SEC Form 4 price — not a live quote)
Grade
C66Well-funded clinical-stage oncology device company with positive regulatory momentum but no revenue and ongoing losses.
Strengths
- $76.9M cash and 9.4-quarter runway (71st pct); current ratio 7.5x
- Clinical de-risking: Japan shonin approval, two FDA Breakthrough Device Designations, pivotal ReSTART readout due 2026
- Encouraging pancreatic and HNSCC interim data
Risks
- No product revenue; accumulated deficit $190M with widening losses
- Binary clinical/regulatory risk on Alpha DaRT
- Negative ROA/ROE (-40%/-55%)
Notable findings
- Cash burnNegative free cash flow (-32.8M)
- Pending merger” On July 7, 2021, we entered into the Merger Agreement with HCCC and Merger Sub
- Insider sellingInsider selling — 6 open-market sale(s) by 1 insider(s) (~$739,170, last 6mo) Form 4 ↗
Key metrics
Return on equity
-55.3%
Return on assets
-40.3%
Current ratio
7.5×
Free cash flow
-$33M
Tangible book value
$77M
Cash & investments
$77M
Cash runway
9q
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-25 | Levy Raphi | Sell | 4.2K | $11.00 |
| 2026-06-25 | Levy Raphi | Sell | 16K | $11.00 |
| 2026-06-23 | Levy Raphi | Sell | 15K | $9.47 |
| 2026-06-23 | Levy Raphi | Sell | 2.5K | $10.00 |
| 2026-06-03 | Levy Raphi | Sell | 18K | $10.90 |
| 2026-06-03 | Levy Raphi | Sell | 15K | $10.76 |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT06202248 ↗ | Alpha Radiation Emitters Device (DaRT) for the Treatment of Non-Metastatic Locally Recurrent Prostate Cancer. Non-metastatic Prostate Cancer, Locally Recurrent Prostate Cancer | NA | Recruiting | 2027-06-01 |
| NCT05323253 ↗ | Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma Recurrent Squamous Cell Carcinoma | NA | Active Not Recruiting | 2027-04-01 |
| NCT05781555 ↗ | Alpha Radiation Emitters Device (DaRT) for Target Treatments of Malignant Tumors Malignant Tumor | NA | Recruiting | 2027-04-01 |
| NCT05632913 ↗ | Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Lung Cancer Recurrent Lung Cancer, Lung Cancer | NA | Recruiting | 2027-02-01 |
| NCT05829291 ↗ | Alpha Radiation Emitters Device (DaRT) for the Treatment of Liver Metastases Liver Metastases | NA | Recruiting | 2027-02-01 |
| NCT06755359 ↗ | Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Advanced Pancreatic Cancer Pancreatic Cancer, Locally Advanced Pancreatic Cancer | NA | Recruiting | 2027-01-01 |
| NCT04068155 ↗ | Alpha Radiation Emitters Device (DaRT) for the Treatment of of Malignant Cutaneous Tumors Skin Cancer, Cutaneous Tumor | NA | Recruiting | 2027-01-01 |
| NCT04534127 ↗ | Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia Skin Cancer, Mucosal Neoplasm of Oral Cavity | NA | Recruiting | 2027-01-01 |
| NCT06026943 ↗ | Alpha Radiation Emitters for the Treatment of Pancreatic Cancer for the Treatment of Locally Advanced Pancreatic Cancer Pancreatic Cancer, Unresectable Pancreatic Cancer | NA | Recruiting | 2027-01-01 |
| NCT06615635 ↗ | Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous SCC for Immunocompromised Patients Squamous Cell Carcinoma, Alpha Radiation | NA | Recruiting | 2026-12-01 |
| NCT05047094 ↗ | Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC Head and Neck Squamous Cell Carcinoma, Skin Cancer | NA | Recruiting | 2026-12-01 |
| NCT03737734 ↗ | Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia (DaRT) Skin Cancer, Mucosal Neoplasm of Oral Cavity | NA | Active Not Recruiting | 2026-12-01 |
| NCT05657743 ↗ | Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer (Feasibility and Safety) Pancreatic Cancer, Unresectable Pancreatic Cancer | NA | Recruiting | 2026-11-01 |
| NCT06910306 ↗ | Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma Recurrent Glioblastoma, Recurrent Gliomas | NA | Recruiting | 2026-11-01 |
| NCT04002479 ↗ | Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer Pancreatic Cancer, Unresectable Pancreatic Cancer | NA | Active Not Recruiting | 2026-10-01 |
| NCT06698458 ↗ | Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer Pancreatic Cancer, Pancreatic Adenocarcinoma | NA | Recruiting | 2026-10-01 |
| NCT03889899 ↗ | Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia. Skin Cancer, Mucosal Neoplasm of Oral Cavity | NA | Recruiting | 2026-06-01 |
| NCT06202118 ↗ | A Study of Diffusing Alpha Radiation Therapy for Patients With Breast Carcinoma in Frail or Elderly Patients. Breast Cancer, Recurrent Breast Cancer | NA | Recruiting | 2026-01-01 |
| NCT07290998 ↗ | Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Recurrent Prostate Cancer Prostate Cancer, Recurrent Prostate Cancer | NA | Not Yet Recruiting | 2028-05-01 |
| NCT06202339 ↗ | Alpha Radiation Emitters Device for the Treatment of Primary and Recurrent Squamous Cell Carcinoma of the Vulva (DaRT). Carcinoma of the Vulva, Recurrent Carcinoma of the Vulva | NA | Not Yet Recruiting | 2026-04-01 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 20-F | 2026-03-09 | 2025-12-31 | 0001213900-26-025174 ↗ |
| 20-F | 2025-03-12 | 2024-12-31 | 0001213900-25-023187 ↗ |
| 20-F | 2024-03-07 | 2023-12-31 | 0001213900-24-020767 ↗ |
| 20-F | 2023-03-09 | 2022-12-31 | 0001213900-23-018883 ↗ |
| 20-F | 2022-03-28 | 2021-12-31 | 0001104659-22-038887 ↗ |